Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Authors
Keywords
-
Journal
BMC CANCER
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-03-13
DOI
10.1186/s12885-023-10698-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients
- (2023) Hui Zhang et al. Frontiers in Oncology
- Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
- (2022) Kenichi Koyama et al. Scientific Reports
- Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR
- (2021) Catarina Silveira et al. Translational Lung Cancer Research
- Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
- (2021) Irina Palacín-Aliana et al. Biomedicines
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
- (2021) Christian Rolfo et al. Journal of Thoracic Oncology
- Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study
- (2020) Takayuki Takahama et al. CANCER
- Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
- (2020) Svenja Wagener-Ryczek et al. BMC CANCER
- Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer
- (2020) Tara Spence et al. JOURNAL OF CLINICAL PATHOLOGY
- Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
- (2020) Charu Aggarwal et al. Nature Reviews Clinical Oncology
- An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
- (2020) Shang-Gin Wu et al. Frontiers in Oncology
- EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
- (2019) Anna Buder et al. Targeted Oncology
- Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer
- (2019) Kangkook Lee et al. LUNG CANCER
- Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA
- (2019) Marzia Del Re et al. Clinical Lung Cancer
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
- (2019) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer
- (2018) Takahisa Kawamura et al. Clinical Lung Cancer
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
- (2018) Gregory P. Kalemkerian et al. JOURNAL OF CLINICAL ONCOLOGY
- Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR -Mutated NSCLC
- (2018) Anna Buder et al. Journal of Thoracic Oncology
- Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival
- (2018) Jin Woo Joo et al. LUNG CANCER
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study
- (2018) Sheng-Kai Liang et al. Oncotarget
- The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
- (2018) Yen-Hsiang Huang et al. Cancer Research and Treatment
- Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
- (2018) Yen-Ting Lin et al. INTERNATIONAL JOURNAL OF CANCER
- Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
- (2018) Tatsuya Nagano et al. Cells
- Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
- (2017) Umberto Malapelle et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
- (2017) Roberta Visconti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance
- (2017) Jianjiao Ni et al. Oncology Letters
- Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
- (2017) Chang Gon Kim et al. Oncotarget
- Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
- (2017) Kentaro Tanaka et al. Oncotarget
- Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study
- (2016) Kaname Nosaki et al. LUNG CANCER
- The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
- (2016) Shang-Gin Wu et al. Oncotarget
- Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
- (2016) D. Zheng et al. Scientific Reports
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan
- (2015) Kuo-Hsuan Hsu et al. PLoS One
- Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib
- (2014) Boe S. Sorensen et al. CANCER
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
- (2010) Stephen B. Edge et al. ANNALS OF SURGICAL ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search